 |
31 May 2012 - Press Announcement: Rhenovia files patents for new treatment of Huntington's disease based on its Biosimulation PlatformRhenovia's discovery of flagship drug candidate RHEDAR™ through biosimulation brings further proof of the high efficiency of this novel method for developing drugs to treat orphan and broader diseases. Mulhouse, France, Cambridge, MA, May 31st, 2012 - Rhenovia Pharma, a leading biotech company in biosimulation applied to the discovery of new medications to treat neurodegenerative, neurological and psychiatric diseases, announces today of a new method, a drug candidate and a novel chemical series for treatment of Huntington's disease (HD). The drug candidate, referred to as RHEDAR™ is thought to re-equilibrate the dynamic biochemical and biophysical balance disrupted in HD. This product is open for out-licensing to the pharma and biotech industry, or for co-development with patient associations and foundations, governmental organizations or investment partners. It is the first time that novel modes of action of a potential therapeutic agent are discovered by biosimulation thus providing a proof of pertinence of this innovative approach for drug discovery and development. For further information we invite you to contact us at info@rhenovia.com |
|
|
